OTLK (Outlook Therapeutics) Other Current Payables: $0.00 Mil (As of Mar. 2026)


OTLK Outlook Therapeutics Inc OTLK
19 GF Score
Price $1.60
! 6 Warning Signs
View Full Analysis

What is Outlook Therapeutics Other Current Payables?

Outlook Therapeutics OTLK +1.18% 19 Other Current Payables is $0.00 Mil as of Mar. 2026. GuruFocus rates OTLK with a GF Score™ of 19/100. The stock has 6 warning signs investors should review.

Outlook Therapeutics's Other Current Payables for the quarter that ended in Mar. 2026 was $0.00 Mil.

Outlook Therapeutics's quarterly Other Current Payables increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) and increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Outlook Therapeutics's annual Other Current Payables stayed the same from Sep. 2023 ($-0.00 Mil) to Sep. 2024 ($-0.00 Mil) but then increased from Sep. 2024 ($-0.00 Mil) to Sep. 2025 ($0.00 Mil).

Outlook Therapeutics Other Current Payables Related Terms

Outlook Therapeutics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics Other Current Payables Chart

Outlook Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.00 -0.00 0.00

Outlook Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OTLK
19GF Score
Outlook Therapeutics Inc OTLK
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Outlook Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.00 Mil mean?
Outlook Therapeutics (OTLK) has a Other Current Payables of $0.00 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Outlook Therapeutics and its competitors.
Is Outlook Therapeutics' Other Current Payables too high?
Outlook Therapeutics' current Other Current Payables is $0.00 Mil. Overall, Outlook Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' Other Current Payables compare to FULC and OBIO?
Outlook Therapeutics' Other Current Payables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current Other Current Payables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current Other Current Payables of $0.00 Mil. The current Other Current Payables is $0.00 Mil. Outlook Therapeutics' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current Other Current Payables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Outlook Therapeutics Business Description

Other Exchanges 41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
19GF Score

Get the complete analysis for OTLK

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.60
Price